ABBV-CLS-7262
Sponsors
AbbVie Deutschland GmbH & Co. KG, Merit E. Cudkowicz, MD, Calico Life Sciences LLC
Conditions
Amyotrophic Lateral SclerosisHealthyVanishing White Matter disease
Phase 1
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
CompletedNCT05763459
Start: 2023-03-24End: 2023-06-02Updated: 2023-06-26
A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262
CompletedNCT06145607
Start: 2023-12-19End: 2024-02-26Updated: 2024-03-08
A Phase 1b/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following Fosigotifator Administration in Adult and Pediatric Subjects with Vanishing White Matter Disease
RecruitingCTIS2023-505704-30-00
Start: 2024-03-22Target: 5Updated: 2025-06-11
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
CompletedNCT06310876
Start: 2024-03-14End: 2024-06-26Updated: 2024-07-01